Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17DJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update
08/28DJGILEAD SCIENCES : The Promising New Cancer Treatment Behind Gilead's $11 Billion..
08/28DJHot Stocks to Watch in the U.S. and Canada
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- Update
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion in Cash
08/24 Cyclicals boost European shares while Dixons Carphone plummets
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/10 Cyclicals and ex-divs send European shares to four-month low
07/31 France's Sanofi raises earnings forecast, pleased with eczema drug uptake
07/31DJSanofi 2Q Net Profit Down 10% at EUR1.04 Billion
07/27DJUNITED THERAPEUTICS : in Settlement Talks With Justice Department -- Update
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/29 UK and industrials prominent in Goldman strategists' M&A target reshuffle
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/20 PAREXEL INTERNATIONAL : Pamplona Capital to take Parexel private for $4.5 billio..
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
06/09 ACTELION : Johnson & Johnson expects to complete Actelion purchase on June 16
06/09 ACTELION : Johnson & Johnson expects to complete of Actelion offer on June 16
06/02DJBluebird Bio stock jumps 7% after Maxim Group upgrades to buy -- MarketWatch
05/31 GILEAD SCIENCES : and GSK go head-to-head with similar HIV drug data
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/15 Thermo Fisher to buy Patheon for $5.2 billion to expand biopharma services
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
P/E ratio 2017 121,11
P/E ratio 2018 83,85
EV / Sales 2017 13,9x
EV / Sales 2018 10,3x
Capitalization 3 215 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC AG192.93%3 793
INCYTE CORPORATION14.83%24 254
QUINTILES IMS HOLDINGS INC32.72%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.82%19 730
ALNYLAM PHARMACEUTICALS, INC.213.97%10 783
SEATTLE GENETICS, INC.20.67%9 108
IONIS PHARMACEUTICALS INC33.58%7 945
QIAGEN NV18.22%7 941
ALKERMES PLC-8.08%7 850
ICON PLC52.25%6 187
INC RESEARCH HOLDINGS INC3.99%5 663
EXACT SCIENCES CORPORATION248.95%5 552
CHARLES RIVER LABORATORIES INTL. INC50.54%5 459
UNITED THERAPEUTICS CORPORATION-16.25%5 218
PRA HEALTH SCIENCES INC49.49%5 162
GALAPAGOS41.02%5 157
BIO-TECHNE CORP19.74%4 604
PUMA BIOTECHNOLOGY INC302.44%4 597
ACADIA PHARMACEUTICALS INC.27.36%4 496
FIBROGEN INC157.24%4 347